Davis Polk advised the joint book-running managers in connection with an initial public offering of 10,586,316 shares of common stock of Black Diamond Therapeutics, Inc. In addition, the underwriters have exercised an option to purchase an additional 1,587,947 shares of common stock. Aggregate gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by Black Diamond Therapeutics, were approximately $231.3 million. Black Diamond Therapeutics’ common stock is listed on the Nasdaq Global Select Market under the symbol “BDTX.”

Based in Cambridge, Massachusetts, Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies that target undrugged mutations in patients with genetically defined cancers.

The Davis Polk corporate team included partners Richard D. Truesdell Jr. and Marcel Fausten and associates Stephen A. Byeff, Eryn E. Gordon, Thomas Chen and Yuchen Han. Partner David R. Bauer and associate Mikaela Dealissia provided intellectual property and technology advice. Partner Po Sit provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post